Recently, the Antibody-Drug Conjugates (ADCs) program’s ‘Recombinant Humanized anti-HER2 Monoclonal Antibody-Maytansine Conjugates for Injection’ (BAT8001) was approved for clinical trials in China. BAT8001 is suitable for multiple cancer disease indications, including HER2 over-expressed metastatic breast cancer as well as metastatic gastric cancer. Bio-Thera is proud that BAT8001 represents a class of novel drugs and also is the independent intellectual property developed by Bio-Thera. Thus far, we have patented the compound and preparation method of this drug and have respectively obtained three patent licenses from the Chinese Patent Office and four patent licenses from the US Patent Office.
